| Market Cap | ₹5,350.7 Cr |
|---|---|
| PE Ratio TTM | 617.34Sector 44.82 |
| RSI | 33.65Neutral Zone |
| Deal value | ₹600 Cr |
| Share of market cap | 11.2% |
Key highlights
- Fundraising limit approved for an indicative amount of up to ₹600 crore
- Proposed instruments include equity shares and fully or partly convertible debentures
- The total fundraise amount represents approximately 11.2% of the company current market capitalization
- Board meeting commenced at 11:00 A.M. and concluded at 11:50 A.M. on October 20, 2026
- Proposed issuance is subject to statutory, regulatory, and shareholder approvals
Capital Raising via Multiple Instruments
Orchid Pharma has initiated a significant capital-raising exercise by securing board approval for an enabling resolution to raise up to ₹600 crore. The board meeting, held on October 20, 2026, authorized the exploration of various funding routes including qualified institutions placement, private placement, and public issues of equity or debt securities. This move aims to provide the company with the financial flexibility to capitalize on emerging market opportunities.
The final issuance remains subject to necessary permissions from shareholders and regulatory authorities, with the specific pricing and timing to be determined as market conditions evolve.
Financial Performance and Market Context
- The company reported a quarterly revenue of ₹304.17 crore for the period ended June 2026, marking a 75.89% year-on-year increase
- Net profit for the same quarter stood at ₹3.22 crore, reflecting a decline compared to previous periods
- Operating profit margin for the latest quarter was recorded at 4.6% against the sector average
- The company currently trades at a TTM P/E of 617.34, significantly higher than the industry P/E of 44.83
- Promoter holding remains stable at 74.45% as per the latest ownership data
Strategic Expansion and Past Milestones
This fundraising proposal follows a similar board approval in September 2025 for ₹504 crore via preferential allotment. Orchid Pharma is currently focused on several high-value projects, including the commissioning of its ₹600-crore 7-ACA biotechnology fermentation manufacturing facility in Jammu, slated for February 2027. Additionally, the company reported a significant 4x quarter-on-quarter expansion in its Europe order book for Exblifep as of May 2026.
The landing of fresh capital on the balance sheet is expected to support these ongoing expansions and enhance the company's manufacturing capabilities in the pharmaceutical sector.
| Date | Announcement | Amount |
|---|---|---|
| 15 Oct 2026 | Board intimation to evaluate fund raising options via equity shares, convertible debentures, NCDs with warrants, QIP, preferential issue, or private/public placementSource: scanx.trade | – |
| 05 Sep 2025 | Board approval for fund raising via equity share issuance through preferential allotment or private placementSource: scanx.trade | ₹504.00 Cr |
What to watch next
- Shareholder meeting for the approval of the ₹600 crore fundraising resolution
- Commissioning of the Jammu 7-ACA fermentation manufacturing facility by February 2027
- Announcement of the next quarterly financial results for the period ending September 2026
| Share price | ₹893.5 |
|---|---|
| Market capitalisation | ₹5,350.74 Cr |
| Revenue (annual) | ₹811.33 Cr |
| Net profit (annual) | ₹20.55 Cr |
| Revenue (latest quarter) | ₹304.17 Cr+28.01% vs previous quarter |
| Net profit (latest quarter) | ₹3.22 Cr-86.44% vs previous quarter |
| P/E (TTM) | 617.34×Sector 44.82× |
| Promoter holding | 74.45%+4.61% QoQ |
| FII holding | 0.93%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Orchid Pharma Ltd regarding the outcome of its board meeting held on October 20, 2026. Market figures from a third-party data provider.
Track Orchid Pharma live
Get the next Orchid Pharma filing on Telegram seconds after it lands. 15 days free.
